Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 20, 2023 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Present at The Menopause Society 2023 Annual Meeting

SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Dr. Andrew Goldstein, Daré Medical Advisor, will...
September 06, 2023 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Participate in Upcoming Investor Conferences

SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and...
September 05, 2023 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Completes Previously Announced Equity Financing

SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the completion of its registered direct offering of common...
August 30, 2023 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Announces $7.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

SAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it has entered into a definitive agreement with an...
August 10, 2023 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update

Conference Call and Webcast Today at 4:30 p.m. ET Second Half 2023 Anticipated Milestones (target indication(s)): XACIATO™ First Commercial SaleOvaprene® (hormone-free monthly contraception) –...
August 09, 2023 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Announces Publication in The Journal of The North American Menopause Society of Positive Efficacy Findings for the Treatment of Menopausal Symptoms from a Phase 1/2 Clinical Trial of DARE-HRT1 Intravaginal Rings

DARE-HRT1 Demonstrated Preliminary Treatment Efficacy for Both Vasomotor Symptoms (VMS) and Genitourinary Syndrome of Menopause (GSM) The North American Menopause Society (NAMS) Guidance on...
August 03, 2023 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Host Second Quarter 2023 Financial Results and Company Update Conference Call and Webcast on August 10, 2023

SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30...
July 31, 2023 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Announces Grant Award Supporting Development of Potential New Therapeutic Intervention for the Prevention of Idiopathic Preterm Birth

Grant Funds Will Support Proof-of-Concept Target Validation Studies for Preclinical Development of a Potential New Approach for the Prevention and Treatment of Idiopathic Preterm Birth Currently no...
July 11, 2023 17:30 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Present at the 9th Annual International Symposium of Drug Delivery Systems

SAN DIEGO, July 11, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the company’s Chief Scientific Officer, David Friend,...
July 11, 2023 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Announces Additional Positive Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women

Sildenafil Cream Demonstrated Statistically Significant Improvement in Sexual Desire, an Exploratory Endpoint; Improvements in Arousal Lubrication, Orgasm and Sexual Desire Seen in the Sildenafil...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right